Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With Lanreotide Depot for GEP-NETs
NCT03043664Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 2017
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Duke University. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03043664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043664.